CL2016001192A1 - Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. - Google Patents

Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.

Info

Publication number
CL2016001192A1
CL2016001192A1 CL2016001192A CL2016001192A CL2016001192A1 CL 2016001192 A1 CL2016001192 A1 CL 2016001192A1 CL 2016001192 A CL2016001192 A CL 2016001192A CL 2016001192 A CL2016001192 A CL 2016001192A CL 2016001192 A1 CL2016001192 A1 CL 2016001192A1
Authority
CL
Chile
Prior art keywords
dhodh
inhibitor
neurodegenerative diseases
treat neurodegenerative
dihydroorate dehydrogenase
Prior art date
Application number
CL2016001192A
Other languages
English (en)
Inventor
James C Dodge
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2016001192A1 publication Critical patent/CL2016001192A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

METODO PARA EL TRATAMIENTO DE ELA QUE COMPRENDDE UN COMPUESTO INHIBIDOR DE DIHIDROORATO DESHIDROGENASA (DHODH); COMPOSICION FARMACEUTICA; UN KIT
CL2016001192A 2013-11-22 2016-05-18 Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. CL2016001192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361908019P 2013-11-22 2013-11-22

Publications (1)

Publication Number Publication Date
CL2016001192A1 true CL2016001192A1 (es) 2017-01-13

Family

ID=52146688

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001192A CL2016001192A1 (es) 2013-11-22 2016-05-18 Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.

Country Status (14)

Country Link
US (1) US20160287549A1 (es)
EP (1) EP3071199A2 (es)
JP (1) JP2016537360A (es)
KR (1) KR20160079123A (es)
CN (1) CN105916522A (es)
AU (1) AU2014352920A1 (es)
CA (1) CA2930429A1 (es)
CL (1) CL2016001192A1 (es)
EA (1) EA201691057A1 (es)
IL (1) IL245541A0 (es)
MX (1) MX2016006678A (es)
PH (1) PH12016500903A1 (es)
TN (1) TN2016000197A1 (es)
WO (1) WO2015077535A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017056104A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Limited Stable pharmaceutical compositions of teriflunomide
CN107382902B (zh) * 2016-05-17 2022-08-12 华东理工大学 噻唑类衍生物及其应用
UA127354C2 (uk) * 2017-11-23 2023-07-26 Іммунік Аґ Спосіб профілактики або лікування хронічних запальних і/або аутоімунних захворювань відофлудимусом
WO2020005189A2 (en) 2018-06-27 2020-01-02 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions comprising teriflunomide
US11877994B2 (en) 2021-08-02 2024-01-23 Immunic Ag Treatment of multiple sclerosis comprising DHODH inhibitors
EP4489745A4 (en) * 2022-03-09 2025-10-15 Kiora Pharmaceuticals Gmbh POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR
TW202444688A (zh) * 2023-03-29 2024-11-16 德商埃慕尼克股份公司 作為nurr1激動劑之維多氟地莫(vidofludimus)及相關結構

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4680299A (en) 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
US5032597A (en) 1983-07-22 1991-07-16 Du Pont Merck Pharmaceutical Method of using phenylquinolinecarboxylic acids and derivatives for lymthoid leukemia treatment in a mammal
US4639454A (en) 1985-01-17 1987-01-27 E. I. Du Pont De Nemours And Company Phenylquinazolinecarboxylic acids and derivatives as cancer chemotherapeutic agents
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
GB8619432D0 (en) 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
GB8619433D0 (en) 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816540A (en) 1987-06-12 1989-03-28 Yasuhiko Onishi Cationic graft-copolymer
US4847381A (en) 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US4968701A (en) 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4861783A (en) 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US4968702A (en) 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
US4918077A (en) 1989-01-25 1990-04-17 E. I. Du Pont De Nemours & Co., Inc. 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
AU649421B2 (en) 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
IL99811A (en) 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
IL102790A (en) 1991-09-17 1996-01-31 Roussel Uclaf 3-Cycloalkyl-prop-2- enamide derivatives
EP0538783B1 (de) 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
GB9200275D0 (en) 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0601191B1 (en) 1992-04-24 1998-07-22 Kyowa Hakko Kogyo Kabushiki Kaisha Novel tetracyclic compound
GB9209330D0 (en) 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
GB9300083D0 (en) 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
JP3272808B2 (ja) 1993-04-28 2002-04-08 協和醗酵工業株式会社 新規四環系化合物
US5393891A (en) 1993-06-08 1995-02-28 The Du Pont Merck Pharmaceutical Company Immunoassay reagents and methods for detecting brequinar and analogs
GB9313365D0 (en) 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
DE69430752T2 (de) 1993-09-28 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Tetracyclische verbindungen
GB9320299D0 (en) 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
GB9322781D0 (en) 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5523408A (en) 1994-03-25 1996-06-04 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
JPH083163A (ja) 1994-06-22 1996-01-09 Kyowa Hakko Kogyo Co Ltd 縮合ピリジン誘導体
GB9520092D0 (en) 1995-10-02 1995-12-06 Hoechst Roussel Ltd Chemical compounds
AU2896097A (en) 1996-05-10 1997-12-05 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
DE19636974A1 (de) 1996-09-12 1998-03-19 Hoechst Ag 2-Cyano-3,5-dihydroxy-hex-2-en- carbonsäureamidderivate
JPH10231289A (ja) 1996-12-06 1998-09-02 Kyowa Hakko Kogyo Co Ltd 四環系キノリン誘導体
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CA2772275A1 (en) * 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань

Also Published As

Publication number Publication date
EP3071199A2 (en) 2016-09-28
IL245541A0 (en) 2016-06-30
KR20160079123A (ko) 2016-07-05
TN2016000197A1 (en) 2017-10-06
CA2930429A1 (en) 2015-05-28
US20160287549A1 (en) 2016-10-06
EA201691057A1 (ru) 2016-10-31
WO2015077535A2 (en) 2015-05-28
CN105916522A (zh) 2016-08-31
PH12016500903A1 (en) 2016-06-20
MX2016006678A (es) 2016-09-13
WO2015077535A3 (en) 2015-08-20
JP2016537360A (ja) 2016-12-01
AU2014352920A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX2015012644A (es) Tratamiento de cataplejia.
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
MX2017005457A (es) Metodos y compuestos agonistas de gip.
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
EA201691421A1 (ru) Гетероарилы и их применение
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2019001011A (es) Compuestos farmaceuticos.
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2015010077A (es) Terapia de combinacion para el tratamiento de neumonia nosocomial.
CL2014002978A1 (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos
MX2017002610A (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112015029462A2 (pt) Inibidores de quinase
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1